Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

What matters most in commercial success: first-in-class or best-in-class?

Subjects

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Value captured as a function of time of market entry and therapeutic advantage.
Figure 2: Value captured by follow-on entrants as a function of time of market entry and therapeutic advantage.

Acknowledgements

The authors gratefully acknowledge the contributions of M. Herant, G. Hersch and B. Howard to this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ulrik Schulze.

Ethics declarations

Competing interests

The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on R&D productivity issues. The research for this specific article was funded by BCG's Health Care practice.

Supplementary information

Supplementary Table S1

(PDF 882 kb)

Supplementary Box S2

Dataset and details of analysis (PDF 475 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schulze, U., Ringel, M. What matters most in commercial success: first-in-class or best-in-class?. Nat Rev Drug Discov 12, 419–420 (2013). https://doi.org/10.1038/nrd4035

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4035

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing